Physician profile
Milenko Lazarevic
NPI 1366544405
$15,371.27
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,189 · 2020: $3,650 · 2021: $3,646 · 2022: $2,383 · 2023: $1,644 · 2024: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,503.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,805.23 | 2019-2023 | Nayzilam, Cimzia, Briviact |
| Astrazeneca Pharmaceuticals LP | $1,486.26 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,339.52 | 2019-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $1,241.17 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $1,227.25 | 2019-2024 | Repatha, Krystexxa, Otezla |
| Pfizer INC. | $1,034.57 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $759.07 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $733.01 | 2019-2024 | Xarelto |
| Abbvie INC. | $670.24 | 2019-2024 | |
| Amarin Pharma, INC. | $556.96 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $530.20 | 2019-2024 | |
| Allergan, INC. | $500.48 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $500.18 | 2019-2023 | Verquvo, Dificid, Januvia |
| Lilly USA, LLC | $435.46 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $311.85 | 2019-2024 | Eliquis |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milenko Lazarevic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.